Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Laserscope Inc.

Division of Endo International PLC
www.laserscope.com

Latest From Laserscope Inc.

BPH: An Expanding Opportunity

Directed energy device-based medical therapies have greatly influenced the way physicians deliver care in a number of medical specialties. One of the most dramatic areas of change has been in the management of benign prostatic hyperplasia, commonly referred to as an enlarged prostate. DE treatments in this area have become so popular there has been a noticeable decline in once standard surgical therapies since the late 1990s as patients have migrated to these less-invasive alternatives. This expansion in BPH DE-based therapies is being driven not only by a shift toward less-invasive treatment options, but also by the rising number of patients susceptible to prostate ailments.
Medical Device

Device M&A: The New Acquirers

A business development panel representing the emerging group of mid-sized device dealmakers that are actively looking for innovative technology from small companies discusses the current state of medtech dealmaking.
Medical Device Business Strategies

Urology: Redefining the Standards of Care

Serving the aging US demographic is a golden opportunity for urology device companies. However, at this year's meeting of the American Urological Association, the field concentrated more on consolidation of older techniques than on breakthrough technologies.
Medical Device

Novacept: A Patient Device Exit Strategy Succeeds

Using an aggressive clinical trials strategy to overcome early setbacks, Novacept is proof a small company can succeed in a big company market, and that a patient exit strategy can pay off for device companies--evidenced by Cytyc's $325 million cash acquisition of Novacept.
Medical Device Strategy
See All

Company Information

Advertisement
Advertisement
UsernamePublicRestriction

Register